干细胞在1型糖尿病治疗中的应用研究进展  

Research Advances in Stem Cell Therapy for Type 1 Diabetes

作　　者：唐珊珊[1] 马东慎[1] 高华山[1] 赵月葵 曹顺秀 金亮[1] 

机构地区：[1]中国药科大学生命科学与技术学院分子生物学教研室,江苏南京210009

出　　处：《药学进展》2016年第3期189-196,共8页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金面上项目(No.31270985;81570696);国家高技术研究发展计划(863计划)(No.2015AA020314);江苏省杰出青年基金(No.BK20140029);中央高校基础科研经费杰出人才引导项目(No.Z114037);江苏高校优势学科建设工程资助项目

摘　　要：1型糖尿病(T1D)是一种慢性、多因素自身免疫性疾病,在发病过程中,会不断破坏胰岛β细胞,最终导致胰岛素分泌不足,严重威胁人类健康。目前,根治T1D的主要方法是胰岛移植,即将移植的胰岛替代体内已被疾病破坏的胰岛细胞,以恢复正常血糖。但是,胰岛移植供体的缺乏和移植免疫排斥反应,给胰岛移植的临床应用带来巨大挑战。近年来,干细胞治疗为T1D提供了一种新疗法,成为T1D治疗领域新的研究热点,为该病的治疗提供了新思路。综述不同来源干细胞——胚胎干细胞、诱导多能干细胞和成体干细胞用于治疗T1D的研究进展。Type 1 diabetes（T1D） is a chronic, multifactorial autoimmune disease that involves the progressive destruction of pancreatic β-cells,ultimately resulting in the loss of insulin production and secretion. Currently, islet transplantation has been accepted as a permanent cure for T1 D, by which the pancreatic islets impaired by the disease is replaced with transplanted islets to restore normal blood glucose level. However, its clinical use is greatly limited by the shortage of islet donors for transplantation and transplantation rejection. Recently, stem cell therapy as a new therapy for T1 D has become a new hotspot in the field of T1 D treatment, providing a new idea for the treatment of the disease. The recent research advances in the application of stem cells from different sources, including embryonic stem cells, induced pluripotent stem cells and adult stem cells, in treating T1 D were reviewed.

关 键 词：1型糖尿病 干细胞治疗 胚胎干细胞 诱导多能干细胞 成体干细胞 

分 类 号：R587.1[医药卫生—内分泌]